Dallas, Texas — According to state and local economic development sources Taysha Gene Therapies plans to invest $2,300,000.00 to build out 29,847 square feet of new space in Dallas. The company plans to occupy the new space at 3000 Pegasus Park Suite 1430 in Dallas, on or about April 1, 2022. According to the company website Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we hope to rapidly translate our treatments from bench to bedside. We have combined our teams proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform an engine for new cure to dramatically improve patients lives.

To learn more about Taysha Gene Therapies, visit http://tayshagtx.com/

Company Contact:
RA Session, Chief Executive Officer
https://www.linkedin.com/in/ra-session-ii-bba8178
214-612-0000

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved